Medicus Pharma has partnered with Swanielle to expand its Phase II trial for treating basal cell carcinoma into the Asia-Pacific region.

Sudo Biosciences has begun a Phase I trial of SUDO-550, a drug candidate designed to treat neuroinflammatory diseases.

GLP-1R injectable drugs are effective in treating obesity, but their success points to a gap in the market: oral alternatives ...

Novocure’s TTFields therapy combined with chemo improved overall survival by 16.2 months compared to 14.16 months with chemo ...

Cantargia has commenced an expanded segment of the ongoing Phase I trial of its antibody, CAN10, with the first participant ...

Qatar Foundation member Sidra Medicine has conducted the industry-sponsored ‘sunRIZE’ trial for paediatric congenital ...

Minghui has reported positive topline outcomes from the Phase III trial of MH004 for treating mild to moderate atopic ...

The results demonstrate the safety and efficacy of Fasenra in the treatment of acute eosinophilic exacerbations in asthma and ...

SELLAS has announced positive data from preclinical studies identifying the ASXL1 mutation as a predictor of response to ...

The Phase III trial of AXS-12 showed results over placebo as the company looks towards a new drug application for its ...

The announcement means the company will be pulling the plug on the CardinALS trial after its ALS drug failed to halt disease ...

Tryptamine Therapeutics (Tryp) has announced the completion of subject dosing in a Phase Ib clinical trial of TRP-8803, for ...